Covid made many things worse, including the lives of asthma patients who were more vulnerable to the disease than others.…
Medtech company Respiri (ASX: RSH) has continued its long path towards commercialisation of its asthma diagnostics device 'wheezo', having entered…
Under new management, medtech company Respiri (ASX: RSH) is poised to enter the lucrative SaaS revenue market by leveraging their…